Abstract: The present invention relates to compositions and fusion proteins containing comprising Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the diagnosis, treatment and/or prevention of tuberculosis infection.

Abstract: The present disclosure provides compositions and methods that are useful for normalizing the amount of signal detected in an assay, such as an immunoassay. The compositions and methods are useful for improving the accuracy of immunoassays, such as immunoassays that detect whether a subject is infected with a retrovirus such as HIV.

Abstract: In the conventional nucleic acid analysis devices and nucleic acid analyzers, there was no technique available for sequencing a single nucleic acid molecule easily and highly efficiently. The present invention enabled a highly efficient single molecule immobilization of nucleic acid with good reproductivity in a short time at a low price by providing small metallic bonding pads at predetermined positions on a support substrate, firmly fixing a hydrophobic linker on the bonding pads, and bonding on to the linker bulky microparticles onto which a single molecule of a nucleic acid sample fragment is immobilized. According to the present invention, in the nucleic acid analysis device which uses a nucleic acid analyzer, the nucleotide read length can be extended and many types of nucleic acid molecule to be analyzed can be analyzed at one time.

Abstract: Disclosed herein are methods of and systems for predicting recurrence of atrial fibrillation comprising protease and protease inhibitor profiling.

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract: The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.

Abstract: Chemical compositions of bioactive compounds and/or bioactive molecules for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases are described. Targeted, passive and programmable/active deliveries of the bioactive compounds and/or bioactive molecules are described. Subsystems for detection of disease specific biomarkers/an array of disease specific biomarkers and programmable/active delivery of the bioactive compounds and/or bioactive molecules in near real-time/real-time are also described.

Abstract: Compositions and methods for use in methods and kits for the detection of an increased risk of pancreatic cancer are provided. Cyst fluid samples isolated from patients that are positive for at least three of the following markers, mucin 1, mucin 2, mucin 5AC, mucin 5B, mucin 6, CEA CAM 1, CEACAM 5, CEACAM 6, CEACAM 7, CEACAM 8, S100-A6, S100-A8, S100-A9 and S100-A11 indicate that such patients are at greater risk for the development of pancreatic cancer when compared to cyst fluid samples isolated from patients lacking these markers.

Abstract: The presence of certain auto-antibodies indicates that a subject has lupus. The auto-antibodies recognise antigens listed in Table 1 herein. These auto-antibodies and/or the antigens themselves can be used as biomarkers for assessing lupus in a subject.

Abstract: The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.

Abstract: The present disclosure teaches that the recombination of homologous sequences of P450 enzymes, with the aid of SCHEMA to predict a resulting protein structure, is able to generate libraries of chimeras with significant functional diversity. Additionally, the members of these libraries demonstrate superior or unexpected new properties, which correlate with other factors that are observable in the library. Thus, the making of libraries of optimized P450 enzymes, the analysis of libraries to identify an optimized subset, and the optimized chimeras with improved or altered functionalities are all taught in the present disclosure.

Abstract: A combinatorial elastic modulus-modified microenvironment microarray (eMEArray) platform and methods for cell-based functional screening of interactions with combinatorial microenvironments. The platform and methods allow for simultaneous control of the molecular composition and the elastic modulus, and combines the use of microarray and micropatterning technologies. The eMEArrays have been used to show that the microenvironment has effects on drug-cell interactions and contributes to therapeutic response.

Abstract: The present invention relates to methods for detecting, enriching, and analyzing rare cells that are present in the blood, e.g., epithelial cells. The invention further features methods of analyzing rare cell(s) to determine the presence of an abnormality, disease or condition in a subject by analyzing a cellular sample from the subject.

Abstract: The present invention provides: a glycopeptide array which is useful for the detection of the binding between a substance to be detected and a glycopeptide; and an array which can inhibit the non-specific adsorption or binding of a substance to be detected without the need of coating any adsorption-inhibiting agent and which has the glycopeptide immobilized thereon. In the present invention, it was found that a glycopeptide that has a molecule having a carbonyl group bound to a peptide moiety thereof can be immobilized on a substrate that is coated with a polymer compound containing a unit having a primary amino group with high efficiency through the carbonyl group.

Abstract: Compositions and methods are provided for nucleotide analogs comprising protein shields for improving enzyme photostability in single molecule real time sequencing. Nucleotide analogs of the invention have a protein shield between the dye moieties and nucleotide moieties of the analog. The protein prevents the direct interaction of the dye moiety with the enzyme carrying out nucleotide synthesis preventing photodamage to the enzyme. The nucleotide analogs of the invention can have multiple dyes and multiple nucleotide moieties.

Abstract: The present invention provides a peptide selected from the following (i) and (ii): (i) a peptide having the amino acid sequence represented by SEQ ID NO: 1 in the Sequence Listing; and (ii) a peptide having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 1 in the Sequence Listing by the conservative amino acid substitution, deletion, addition, or insertion of 1 to (inclusive) amino acids except at the 1st Xaa to the 11th Xaa counting from the amino terminus.

Abstract: The invention provides compositions and methods for determining patient compliance with a smoking cessation program, and monitoring the patient for physiological recovery from the deleterious effects of smoking, with particular emphasis on those effects that impact risk of cardiovascular disease and development of cancer. The invention also provides compositions and methods for treating a subject according to the patient compliance with the smoking cessation program.

Abstract: An object of the invention is to provide a peptide having a stabilized secondary structure. The present invention provides a peptide having a secondary structure stabilized by a crosslinked structure and containing at least one combination of a special amino acid of the formula (I): (wherein, (A) represents a single bond or a linking group having, in the main chain thereof, from 1 to 10 atoms; (B) represents a group containing at least one ? bond; (C) represents a hydrogen atom or an alkyl group which may be substituted with a substituent; and X represents a group substitutable by a substitution reaction with a sulfanyl group) and an amino acid having, in the side chain thereof, a sulfanyl group; and having the crosslinked structure formed through a thioether bond between the side chain of the special amino acid residue and the sulfanyl group.

Abstract: The present invention provides novel antigen-binding proteins derived from human germline VH domains, having improved expression and improved biophysical characteristics.

Abstract: The present disclosure includes methods of improving the quality of poultry and the efficiency of its production. Specifically, single nucleotide polymorphisms (SNPs) have been identified in signature domains and conserved residues found in ?-class turkey Glutathione S-Transferase (GSTA) genes. These SNPS correlate with aflatoxin resistance in turkeys. Thus, methods of screening for the relevant SNPs using polynucleotides and anti-peptide antibodies, kits that include these tools, and methods of breeding aflatoxin resistant flocks are provided herein.

Abstract: The invention describes accurate and flexible methods and kits for conducting multi-analyte microarrays through the use of Tag-specific antibodies and analyte-specific Tag-anchored antibodies.

Abstract: Provided are methods and compositions for detection of levels, activity, or expression of cytokines so as to determine a cytokine signature. A cytokine signature of a subject can be compared to a control or reference value(s) and differences there between used in the diagnosis or monitoring of a neuroimmune disease or a retroviral infection.

Abstract: Provided is a method for preparing antibodies against a protein of interest, through which highly specific antibodies against all proteins can be effectively and rapidly prepared with low cost, and the epitope to which the antibody is directed can be determined, so that a library covering epitopes on the surface of the proteins of interest and a library of antibodies against all the epitopes can be established. The antibodies are proved to be useful in detection, protein function investigation and antibody pharmaceuticals.

Abstract: The présent invention relates to a method for manufacturing an analysis device including torpédo membrane fragments immobilized at the surface thereof, to the resulting analysis device, and to the use of said device for detecting, purifying, and characterizing molécules acting on nicotinic acetylcholine receptors. The présent invention is useful in the field of monitoring seafood, monitoring neurotoxic phytoplankton for the shellfish industry, monitoring the quality of bathing waters along tourist beaches, the field of monitoring fresh water reserves, the field of médical research, the field of the biological analysis and characterization of molécules, e.g., non-radioactive assays of the movement of the ligand-receptor bond on an ELISA-type microplate, thereby enabling compétitive agonists and antagonists of targets to be detected, e.g., of highly sensitive receptors.

Abstract: The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a VH, the Cys may be introduced at any one of positions (47-49) and any one of positions (67-71), based on Kabat numbering; in one example, the Cys may be introduced at positions (49) and (69), based on Kabat numbering. In the case where the sdAb scaffold is a VL, the Cys residues may be introduced at any one of positions 46-49 and any one of positions (62-66), based on Kabat numbering; in one example, the Cys residues may be introduced at positions (48 and 64), based on Kabat numbering.

Abstract: A method to identify a peptide and/or its encoding DNA, wherein the peptide binds to a T-cell receptor and/or an NK-cell receptor and/or an NKT-cell receptor, the method comprising: providing a carrier to which is attached a peptide and its encoding DNA; providing an MHC and/or an MHC-like molecule; and exposing the peptide to a T-cell receptor and/or an NK-cell receptor and/or an NKT-cell receptor in the presence of the MHC or MHC-like molecule.

Abstract: Methods and devices are provided for preparing a protein array having a plurality of proteins. In one embodiment, the method includes providing a plurality of nucleic acids each having a predefined sequence and expressing in vitro a plurality of proteins from the plurality of nucleic acids. In another embodiment, protein arrays having a solid surface and a microvolume are also provided. The solid surface can have a plurality of anchor oligonucleotides capable of hybridizing with a plurality of nucleic acids. The microvolume can cover each of the plurality of anchor oligonucleotides and can be configured to produce a polypeptide from each of the plurality of nucleic acids.

Abstract: Methods, substrates, and devices related to arrays of optical confinements having surfaces with high levels of bias. Substrates having transparent or silica based portions and opaque or reflective portions are treated with 1) a selective passivating agent, that selectively coats the opaque or reflective regions, 2) a functionalizing agent such as a coupling agent, and 3) a selective removal agent, which selectively removes functionalizing agent from the passivated opaque or reflective surfaces.

Abstract: The invention provides a method for determining a Systemic Lupus Erythematosus-associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table 1, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table 1 is indicative of a Systemic Lupus. The invention also provides an array and a kit suitable for use in the methods of the invention.

Abstract: Provided herein is a library of antibodies, wherein the library of antibodies can comprise a plurality of monoclonal, monospecific, or immunoprecipitating antibodies. Also provided herein is a method for producing and using the library of antibodies.

Abstract: Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Each compound has the formula: wherein: Z is a trityl derivative; X, the reactivity function, covalently binds to amino acid side chains of proteins; Y, the selectivity function, modulates binding of X to the amino acid side chains in proteins such that X binds to fewer proteins when Y is present than in its absence; and Q permits separation or immobilization of the capture compound. Automated systems for performing the methods also are provided.

Abstract: The present invention provides methods for the assessment of risk of developing lung cancer in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing lung cancer, and the suitability of a subject for an intervention in respect of lung cancer. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.

Abstract: The present invention provides methods for the assessment of risk of developing chronic obstructive pulmonary disease (COPD), emphysema or both COPD and emphysema in smokers and non-smokers using analysis of genetic polymorphisms.

Abstract: Coated nanoparticles comprising a core surrounded by a shell that increases the reflectance of the nanoparticle, wherein the coated nanoparticle does not include a Raman-active molecule, are provided. Test devices and immunoassay methods utilizing the coated nanoparticles are provided.

Abstract: A method for detecting an inflammatory disease in a subject is disclosed. The method comprises the steps of (a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from the subject; and (b) comparing the level of expression of said one or more inflammatory disease markers in the biological sample to a normal level of expression of the one or more inflammatory disease markers, wherein the one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5. Also disclosed are a method for monitoring the course of treatment for an inflammatory disease in a subject and a kit for detecting an inflammatory disease in a subject.

Abstract: The present invention provides arrays comprising polypeptides associated with extracellular matrix that can be used to isolate, differentiate, or culture certain cell types including stem cells, cancer cells, and/or primary hepatocytes. The array comprises at least a pair of polypeptides that comprise a polypeptide associated with extracellular matrix or functional fragments thereof. The invention also provides for methods of diagnosing and/or prognosing a certain disease or disorder through contacting a cell sample from a patient with an array comprising at least a pair of polypeptides that comprise a polypeptide sequence associated with extracellular matrix or functional fragments thereof.

Abstract: The invention relates to point of care diagnostic disposables, devices, methods, and systems for diagnosing or predicting prostate cancer. The present invention employs biomarker specific reagents in disposable cassettes or lab cards for use as analyzers, as well as software to evaluate and report test results. The system promises to improve point of care in vitro diagnostics.

Abstract: A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, preferably human Tenascin, that binds to human TNF? including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: Provided is a device that can detect cells or bacteria in units of a single cell or bacterium, and can further measure the amounts of activity of cells or bacteria or responses of the cells or bacteria to drugs in units of a single cell or bacterium. A plurality of partitioned regions each having about the same size as a cell or a bacterium is provided, and a plurality of types of electrical sensors 201 and 202 are arranged in each partitioned region.

Abstract: Embodiments herein relate to the field of screening tools for fetal/maternal wellness, and, more specifically, to biomarkers for gestational diabetes. In various embodiments, the methods may provide non-invasive and minimally-invasive screening tools for gestational diabetes that involve detection of changes in a proteomic profile of a test sample relative to a reference sample. In particular embodiments, the method may include determining whether a proteomic profile of a test sample from the subject includes at least one expression signature characteristic of gestational diabetes, wherein the proteomic profile comprises information on the expression of glycosylated fibronectin and glycosylated PSG, for example information on levels of fibronectin-SNA or a fibronectin-antibody complex, and PSG-AAL or a PSG-antibody complex.

Abstract: Rheumatoid arthritis and other autoimmune diseases are diagnosed by multiplex assays for antibodies to a panel of antigens that includes cyclic citrullinated peptide and at least five members of a list that includes BRAF1 506-525, BRAF2 656-675, Vimentin (protein) citrullinated, Vimentin 415-433 cit cyclic, Vimentin 58-77 cit3 cyclic, Clusterin 231-250 cit sm1 cyclic, Fibrinogen A 556-575 cit sm cyclic, Fibrinogen A 616-635 cit sm cyclic, Histones2A H2A/a 1-20 cit sm2 cyclic, Filaggrin 48-65 cit2v1 cyclic, BRAF (catalytic domain from v raf murine sarcoma viral oncogene homologue B1, amino acids 416-766).

Abstract: Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of CCL8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-CCL8 antibody is disclosed. The method of the present invention enables diagnosis of the onset of graft-versus-host disease and monitoring of the progress, in particular, differential diagnosis between graft-versus-host disease and an infectious disease. The present invention also provides a method for treating graft-versus-host disease utilizing the anti-CCL8 antibody.

Abstract: A microarray-based assay is provided, which is used for analyzing molecular interactions, including polynucleotides, polypeptides, antibodies, small molecule compounds, peptides and carbohydrates. Such method comprises labeling a target molecule with a luminophore, coupling the target molecule to a particle, and binding to a probe molecule on microarray. In particular, multiplexed genetic analysis of nucleic acid fragments can be implemented. Specific genes, single nucleotide polymorphisms or gene mutations, such as deletions, insertions, and indels, can be identified. This technology, with high sensitivity, enables the detection and interpretation of molecular interactions in an efficient way.

Abstract: At least 13 genes chosen among a set of 28 genes for carrying out a method for identifying at least 66% of patients of those having a survival rate of at most about 20% at 30 months, among a population of patients afflicted by lung cancer having an estimated survival rate of at least 30% at 30 months based on the diagnosis of the lung cancer according to histopathological criteria.

Abstract: At least one element for the implementation of a prognosis method, preferably in vitro, of the survival rate of a patient afflicted by a lung cancer, the lung cancer being previously classified as a lung tumour selected from squamous cell carcinoma (SQC), adenocarcinoma (ADK), large cell neuro-endocrine tumours (LCNE) and basaloid tumours (BAS).

Abstract: Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.

Abstract: The present invention provides a fibronectin type III (Fn3) molecule, wherein the Fn3 contains a stabilizing mutation. The present invention also provides Fn3 polypeptide monobodies, nucleic acid molecules encoding monobodies, and variegated nucleic acid libraries encoding such monobodies. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform the methods.

Abstract: The present invention generally relates to various peptides and particles, for example, for use in screening of particle- or bead-based peptide libraries. In one aspect, the present invention is generally directed to articles including peptides attached to one or more particles, which may have structures such as (particle)-M-Q-Zn-X-J, (particle)-M-Q-Zn—X1—X2—X3—X4—X5-J, (particle)-M-R—Zn—X1—X2—X3—X4—X5-J, (particle)-M-R—X1—X2—X3—X4—X5Zn-Q-J, (particle)-M-X1—X2—X—3X4—X5—Zn—R-J, etc., where M is a methionine residue, M1 is a cleavable linker residue, Q is a group able to enhance intensity and/or sensitivity of mass spectrometry, X comprises one or more amino acid residues, n is a positive integer, Z is a covalent bond or a spacer, and J is an end-group. In some embodiments, the spacer may comprise a structure such as:(I). Other aspects of the present invention generally relate to methods of using such articles, e.g.

Abstract: The present invention is a method and kit for determining responsiveness of a subject to treatment with a Type I interferon based upon the expression of gene signatures shown to be stimulated by interferon. A method for testing the propensity of a test compound to induce a Type I interferon response is also provided.